8-K: KalVista Pharmaceuticals Secures Landmark FDA Approval for EKTERLY, First Oral On-Demand HAE Treatment

KalVista Pharmaceuticals, Inc. announced the U.S. FDA approval of EKTERLY (sebetralstat), the first and only oral on-demand treatment for acute attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

Summary

• The U.S. Food and Drug Administration (FDA) has approved EKTERLY (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
• EKTERLY is the first and only oral on-demand treatment for HAE, addressing a significant unmet need in the treatment landscape.
• The FDA approval was based on data from the Phase 3 KONFIDENT clinical trial, which was published in the New England Journal of Medicine in May 2024.
• The KONFIDENT trial, the largest clinical trial ever conducted in HAE, randomized 136 HAE patients from 66 clinical sites across 20 countries.
• EKTERLY demonstrated significantly faster symptom relief, reduction in attack severity, and attack resolution compared to placebo, with a safety profile similar to placebo.
• Further support came from the KONFIDENT-S open-label extension trial, which as of September 2024, showed patients treated attacks in a median of 10 minutes following onset.
• Most recent KONFIDENT-S data indicated that the beginning of symptom relief occurred in a median of 1.3 hours among attacks involving the larynx, the abdomen, and for breakthrough attacks among patients receiving long-term prophylaxis.
• KalVista Pharmaceuticals will launch EKTERLY in the U.S. immediately, with physicians able to write prescriptions as of July 7, 2025.
• The company has established 'KalVista Cares,' a comprehensive patient support program offering personalized services, including assistance with insurance coverage and access support.
• The Wholesale Acquisition Cost (WAC) price for EKTERLY is $16,720 per dose, with each pack containing two doses, comparable to current branded injectable products.
• The U.S. on-demand HAE market is projected to grow from $650 million to $1.2 billion with the introduction of EKTERLY.

Sentiment

Score: 9

Explanation: The FDA approval of EKTERLY as the first and only oral on-demand treatment for HAE is a transformative event for KalVista, addressing a significant unmet medical need and opening a new market segment. The strong clinical data, immediate U.S. launch plans, and global expansion strategy indicate substantial commercial potential and a highly positive outlook for the company.

Positives

• FDA approval of EKTERLY (sebetralstat) as the first and only oral on-demand treatment for hereditary angioedema (HAE) in patients aged 12 years and older.
• EKTERLY addresses a significant unmet medical need by providing a convenient oral alternative to previously available injectable or subcutaneous HAE treatments.
• Clinical trial data from the Phase 3 KONFIDENT trial demonstrated significantly faster symptom relief, reduction in attack severity, and attack resolution compared to placebo.
• The drug was well-tolerated with a safety profile similar to placebo across both KONFIDENT and KONFIDENT-S trials.
• Real-world data from the KONFIDENT-S open-label extension trial showed patients treated attacks in a median of 10 minutes following onset, and achieved symptom relief in a median of 1.3 hours for laryngeal, abdominal, and breakthrough attacks.
• KalVista Pharmaceuticals is initiating an immediate U.S. launch, with product available in the channel by mid-July 2025, indicating readiness for commercialization.
• The establishment of 'KalVista Cares' provides comprehensive patient support, including insurance navigation and access assistance, which can facilitate patient adoption.
• EKTERLY has the potential to become the foundational treatment for HAE management worldwide, with multiple regulatory applications under review in key global markets and ongoing studies for younger pediatric patients (2-11 years).

Risks

• Plans regarding commercialization of EKTERLY may not fully materialize or prove incorrect.
• Expectations from current clinical trials may not be met.
• The execution of the Phase 3 clinical trial for sebetralstat as designed may face unforeseen challenges.
• Uncertainties exist regarding the safety, efficacy, timing, and ability to complete clinical trials, release data results, and obtain additional regulatory approvals for sebetralstat and other candidates in development.
• The ability of sebetralstat to effectively treat HAE may differ from current expectations.
• The Company's ability to develop, obtain additional regulatory approval for, or commercialize any product candidate is subject to risks and uncertainties.
• The Company's ability to protect its intellectual property may be challenged.
• Potential impact of global business or macroeconomic conditions, including inflation, rising interest rates, actual or perceived instability in the global banking system, and geopolitical conflicts, could adversely affect results.
• The sufficiency of the Company's cash, cash equivalents, and investments to fund its operations is a risk factor.

Future Outlook

KalVista Pharmaceuticals plans immediate U.S. commercialization of EKTERLY, aiming for it to become the foundational HAE treatment globally. The company anticipates further regulatory approvals and launches in Germany and Japan in the second half of 2025, followed by the UK and other global markets in 2026. Ongoing studies are exploring EKTERLY's use in children aged 2 to 11.

Management Comments

• "EKTERLY enables people to treat attacks the moment symptoms begin, wherever they are. This approval affirms the strength of our science and deep commitment to the HAE community." Ben Palleiko, CEO of KalVista.
• "EKTERLY has the potential to become the foundational treatment for HAE and our focus now is on delivering it to the people who need it." Ben Palleiko, CEO of KalVista.

Industry Context

The HAE treatment landscape has historically been dominated by injectable on-demand therapies, which often present significant treatment burdens, leading to delayed intervention or untreated attacks. EKTERLY's approval as the first and only oral on-demand treatment represents a transformative advancement, offering a more convenient and accessible option. This aligns with global treatment guidelines that emphasize early intervention and patient self-administration, potentially shifting the standard of care and improving overall disease management for HAE patients.

Comparison to Industry Standards

• Prior to EKTERLY, all U.S. approved on-demand HAE treatment options required intravenous or subcutaneous administration, such as Firazyr and icatibant, which carry a significant treatment burden.
• Injectable therapies often result in delayed intervention, with an average wait time of 3.8 hours for adults and 7.7 hours for adolescents to treat an attack, and 1/3 to 1/2 of attacks going untreated.
• EKTERLY provides an oral option, empowering patients to treat attacks early without the need for needles or the pain associated with injections, offering greater independence and control.
• EKTERLY's clinical data demonstrated rapid symptom relief (median 2.0 hours in KONFIDENT, 1.3 hours for specific attacks in KONFIDENT-S), which, combined with its oral administration, facilitates earlier treatment compared to the logistical challenges of injectable options.
• The Wholesale Acquisition Cost (WAC) price of $16,720 per dose for EKTERLY is comparable to current branded injectable products, which range from $11,000 to $17,000 per dose, positioning it competitively within the existing market pricing structure.

Stakeholder Impact

• **Shareholders**: Highly positive impact due to the significant regulatory milestone, which is expected to drive substantial revenue growth from a novel product in a rare disease market, and the clear path for global expansion.
• **Patients (HAE)**: Extremely positive impact by providing a convenient, oral, on-demand treatment option that reduces treatment burden, enables earlier intervention, and has the potential to significantly improve their quality of life and disease control.
• **Healthcare Providers**: Positive impact by offering a new, highly effective, and patient-preferred treatment option that aligns with guidelines for early intervention and patient empowerment, simplifying administration compared to existing injectable methods.
• **Employees**: Positive impact due to the company's successful product launch and growth, potentially leading to increased job security, new opportunities, and a strengthened market position.

Next Steps

• Immediate U.S. launch of EKTERLY.
• Physicians can begin writing prescriptions for EKTERLY as of July 7, 2025.
• Product expected to be in the channel by mid-July 2025.
• HCP appointments are in place for the next two months.
• HCP speaker lunches at over 80 sites will begin mid-July 2025.
• An email campaign to over 2,900 patients is underway.
• Patient speaker programs will begin mid-July 2025.
• Engagement with over 1,200 community members at the HAEA Patient Summit from July 10-13, 2025.
• Anticipated launches in Germany and Japan in the second half of 2025, subject to regulatory approval.
• Anticipated launches in the UK and rest of the world in 2026, subject to regulatory approval.
• Ongoing KONFIDENT-KID trials exploring EKTERLY's use in children aged 2 to 11.

Key Dates

Recommendation

Keywords

Hereditary Angioedema, HAE, EKTERLY, sebetralstat, FDA approval, oral treatment, on-demand therapy, plasma kallikrein inhibitor, rare disease, biopharmaceutical, clinical trial, KONFIDENT, KONFIDENT-S, KalVista Pharmaceuticals